The Dr. Hyman Show - The Future Of Mental Health: Psychedelic Medicine For Depression, Addiction, Trauma, And More with Dr. Pamela Kryskow

Episode Date: November 15, 2023

This episode is brought to you by Rupa Health, ButcherBox, Joovv, and ARMRA. Mental health problems are the number one driver of indirect healthcare costs, loss of productivity, and diminished quality of life. Yet, we aren’t very successful at treating them with modern medicine.  Today on The Doctor’s Farmacy, I am excited to talk to Dr. Pamela Kryskow about the renaissance of psychedelic medicine and how these compounds are finally being recognized as powerful tools for overcoming hard-to-treat health issues like PTSD, depression, addiction, and more.    Dr. Pamela Kryskow is a medical doctor and the medical lead of the non-profit Roots To Thrive Psychedelic Assisted Therapy Programs, which treats people with PTSD, depression, anxiety, substance use challenges, and with end-of-life distress. She is a founding board member of the Psychedelic Association of Canada and the medical chair of the Vancouver Island University Post Graduate Certificate in Psychedelic Medicine-assisted Therapy. Her ongoing research includes psilocybin, MDMA, ketamine, microdosing, front-line healthcare workers, and first responder's mental wellness. Prior to studying medicine, she was a City of Coquitlam Firefighter for eight years and a provincial forestry firefighter for four seasons.  This episode is brought to you by Rupa Health, ButcherBox, Joovv, and ARMRA. Access more than 3,000 specialty lab tests with Rupa Health. You can check out a free, live demo with a Q&A or create an account at RupaHealth.com today. For new members of ButcherBox, you can receive New York strip steaks for a year PLUS $20 off your first order. Go to ButcherBox.com/farmacy and use code FARMACY. Visit Joovv.com/FARMACY to take advantage of these unbeatable Black Friday deals. Don't miss out on this limited-time offer! Sale ends 11/27. Receive 15% off your first order of ARMRA Colostrum. Go to tryarmra.com/MARK or enter MARK to get 15% off your first order. Here are more details from our interview (audio version / Apple Subscriber version): The history and resurgence of psychedelic medicine (8:36 / 6:44) Effectiveness and cost savings of psychedelic therapy (10:00 / 8:07) Psilocybin and depression treatment (12:48 / 10:55) How psychedelics work in the brain (18:34 / 16:40) Pamela’s real-world experience providing psychedelic therapy (28:43 / 24:28) Microdosing psychedelics (43:40 / 39:25) Government regulation of psychedelic medicine in Canada (53:11 / 48:56) The future of psychedelic medicine (1:00:51 / 56:37) Learn more at rootstothrive.com.

Coming up on this episode of The Doctor's Pharmacy. There's parts of our brains that just don't talk most of the time. And under the influence of these psychedelics is that those parts of the brain don't connect. And that gives us a possibility of having new ways of knowing, new ways of interpreting. Hey everyone, it's Dr. Mark. I have a question for all you healthcare practitioners listening to this show. How much time do you spend ordering functional medicine lab tests? Well, lab work is a critical tool for functional medicine.

It helps practitioners find the root cause of illness. But the process of ordering, managing, and tracking lab results can take hours of time away from actually caring for your patients. And that is why I want to talk to you about Rupa Health, the absolute best way to order testing from over 30 different lab companies like Genova, Dutch, DSL, and lots more. Rupa makes ordering labs ridiculously simple, which means not only are you able to spend less time on tedious processes, but it also allows you to provide a higher standard of care for your patients. If you're not already one of the tens of thousands of healthcare practitioners using Rupa Health, make sure to go sign up for a completely free account at rupahealth.com.

That's R-U-P-Aalth.com. I'm always being asked how to source high quality meat and seafood. So I wanted to share one of my favorite resources with you that I use to get high quality protein in my own diet. Unfortunately, most meat and seafood at the grocery store is not serving our health. Conventionally raised animals have higher levels of inflammatory fats, not to mention antibiotics, hormones, and other harmful compounds that we just shouldn't eat. And it's not so nice for the animals either. And that's why I love ButcherBox. They make it super easy to get humanely raised meat that you can trust by delivering right to your doorstep. ButcherBox has everything you could want, like 100% grass-fed and grass-finished beef,

and the shipping is always free. ButcherBox is committed to humanely raised animals that are never given antibiotics or added hormones, and since they take out the middleman, you get an extra savings. There is a major stipulation I always tell my patients about when it comes to animal protein. Quality needs to be a priority. And with ButcherBox, you can feel good knowing you're getting the highest quality meat and seafood that will help you thrive. Right now, ButcherBox has a special offer. New members can get New York strip steaks for a year, plus $20 off your first order. Just go to butcherbox.com forward slash pharmacy and use the code pharmacy, F-A-R-M-A-C-Y. And now let's get back to this episode of The Doctor's Pharmacy.

Welcome to The Doctor's Pharmacy. I'm Dr. Mark Hyman. That's pharmacy with an F, a place for conversations that matter. If you've been listening to the news or watching TV shows online, you probably have heard about the psychedelic revolution, which is taking the scientific world by storm and medicine and psychiatry by storm, by transforming our way of thinking about mental illness. It really is a very different paradigm. And I think it's a renaissance that we haven't seen in psychiatry since the advent of Sigmund Freud, for that matter. And today we're going to have a chance to talk to someone who's deep in the work of this, not just in the theory of it, but in the practice of it. And this is Dr. Pamela Crisco, who's a medical doctor and the medical lead of a nonprofit called

Roots to Thrive, a psychedelic-assisted therapy program, which treats PTSD, depression, anxiety, substance abuse, and end-of-life distress. She's a founding board member of the Psychedelic Association of Canada and the medical chair of the Psychedelic Association of Canada and the medical chair of the Vancouver Island University Postgraduate Certificate in Psychedelic Medicine Assisted Therapy. Her ongoing research includes psilocybin, MDMA, ketamine, microdosing of psilocybin, and helping frontline healthcare workers and first responders mental wellness. She was also a firefighter for eight years in Canada and worked in provincial forestry firefighter for four seasons, which is pretty amazing. And she's also a good friend and a

brilliant physician and works with a team of researchers in Canada doing extraordinary research around how to bring psychedelic medicine into practice. And in America, we haven't quite gotten there, but there are some more free provisions in Canadian law that allow for this type of work to be done under medical supervision. And so she has a lot of experience and a lot of practical experience,

as well as the research experience to help us understand and navigate this often very confusing and often complicated field of psychiatric medicine. So welcome Pam. Hi Mark, great to be here. So welcome, Pam. Hi, Mark. Great to be here. Thanks for having me. So I want to kind of just first start off by saying that so much of traditional psychiatry has been such a failure. When you look at the treatment of depression, addiction, anxiety, PTSD, the increasing rates of suicide, the increasing rates of opioid addiction, anxiety, PTSD, the increasing rates of suicide, the increasing rates of opioid addiction, the incredible existential distress that many of us are feeling even

if we don't have a mental illness. And traditional psychiatry has been focused on talk therapy originally and then increasingly in the last 40, 50 years on psychiatric medication, which is the third leading category of drugs sold after, I think, statins and acid-blocking drugs, which are lifestyle diseases. And they've been found to be somewhat effective for some patients in extreme situations, but they're generally not that effective. And what we're seeing here with psychiatric medicine is a kind of a rethinking of how we approach the root causes rather than trying to cover over symptoms. There may be a way to deal with some of the root causes of the trauma. And, you know, a colleague of yours, and I'm sure

some of you know well, Gev Armate lives in Vancouver near where we also live in British Columbia. And he talks about the trauma we all experience as we grow up and that we're all, whether we're subject to big traumas, you know, he calls it the big trauma with a big T, which is, you know, sexual abuse, violence, things like that, or little traumas, which is just, you know, being neglected by your parents or being bullied at school or, you know, not fitting in or dealing with the stresses of just being a human being in the 21st century, all impacts us and is driving so much of what's underlying mental illness. And it seems to me that for the first time, we have a model for helping people understand and deal with their traumas in ways that gets them free, rather than just having to, quote, manage their psychiatric diseases.

So I think, you know, can you kind of talk to us about the sort of revolutions in psychedelic medicine that's happened over the last even five years and how it's being now recognized and being implemented through programs like yours, like Roots Thrive and others, and research you're doing to treat these really treatment-resistant problems. You know, it makes me laugh. Like, you know, in the emergency room, when someone comes in with a heart attack, after everything fails, we give them intravenous magnesium to calm their heart down. Why don't we do that at the beginning? Why don't we deal with, like, the root causes at the beginning

rather than as the last resort therapy? So can you talk about the different types of psychedelics that are being out there used and how they kind of work to deal with some of these really recalcitrant mental health problems, psilocybin, ketamine, MDMA, and your experience with them? Well, thank you for mentioning Dr. Mate Gabor as a colleague. And he really opened up a lot of doors here for us. He really, you know, the whole medical field and even like he hit the population before the medical field really even really caught up to what he was saying. You know, he was saying like, these are symptoms. The addiction is, is not, is, is just the, the symptom of trying to soothe normal self-soothing behaviors. We're all trying to feel better. And he really opened the doors on how we look at addiction, not as a, you know,

we were looking at addiction as an illness when really it's a symptom of soothing the trauma. So, you know, so much thanks and gratitude to Dr. Mate for all the doors he opened for us. And really having us start to think differently on, well, approaching these problems and especially approaching them with psychedelics. He was certainly a leader, you know, working with ayahuasca in Canada and trying to get that until Health Canada stopped them. But, you know, there's so many of these medicines, like you alluded or you talked about, are coming back and how exciting. Because, again, as you said, you know, we've been in this area of psychiatry that's been biological.

Oh, you have a problem? Here's a pill. As opposed to, like you said, getting to that root cause. And I think we in medicine, you know, are like, no, we're ready. Like we, we haven't liked that system. And we really do want to get to the fundamentals of health. And so we have these psychedelic medicines that are coming back, you know, and, and, you know, the history of it too, is really important that people know, like, especially in Canada, LSD and psilocybin were used. They were used in Saskatchewan and Weyburn Mental Hospital.

They were used very successfully for alcoholism, for substance use, for treatment-resistant depression. And then we had the war on drugs that kind of shut it all down. Was that in the 60s this was going on? Yeah, in the 50s and the 60s. And shout out to Dr. Erica Dick, who is a brilliant Canadian historian and has really chronicled going back into these patient archives and reading the patient's description of what they had before and how they felt after with these medicines. And, you know, you asked, like, how are these medicines coming back? And, you know, over the last five years, definitely this is, you know, again, shout out. I always need to really acknowledge who whose shoulders we're standing on. And, you know, Roland Griffiths really and his team at Johns Hopkins, they really opened the door. You know, they were persistent and they got, you know, the first trials through to to use psilocybin for end of life to show us that this was possible.

And I think that opened a lot of our eyes up in medicine that, whoa, maybe these are going to come back. Maybe this is going to be a possibility again. And as many of your listeners will know, and of course, you know, we're seeing lots of emerging evidence for psilocybin for treatment resistant depression, for distress at end of life, so depression and anxiety at end of life. We've had a couple clinical trials now for substance use disorders, such as alcohol use, like two or three sessions with psilocybin, you know, having durable effects going out, you know, 12 and 24 months, tobacco cessation, going out with two or three sessions going out. And when you think of the billions of dollars we spend on pharmaceuticals to help these exact problems, and the durability of those effects are like really hovering at 30

to 40% success rate. And sure, you got compared to traditional success rates. And, and sure. How does that compare to traditional success rates? Well, that's what I mean. Like you take a medicine that you would prescribe as a physician for let's say tobacco cessation, you know, a 12 week course of the medicine that in my, in my patient case that they're, you know, doing it every two, three years, you know, and are even more regularly and still not quitting their tobacco. Whereas the psilocybin we're looking at two or three sessions and, you know, and are even more regularly and still not quitting their tobacco. Whereas the psilocybin,

we're looking at two or three sessions and, you know, still a success rate close to 70% two years later. You know, that is these kinds of numbers. We don't see an addiction therapy. No, I mean, yeah. Recidivism is, you know, people it's very high and, you know, success rates are, you know, in the lowest, you know, double digits, like 10, 20%, if that. And, and the same thing with, you know, food addiction, with depression, treatment resistant depression, with, you know, so much of the psychiatric problems people have and, and yet, and PTSD, you know, and these are things that debilitate society that costs enormous amounts of money. And I did a review of, you know, the economic impact of chronic disease. And it was estimated

that it was going to cost society $95 trillion over the next 35 years. It's an enormous amount of money. I was like, it's almost $3.5 trillion a year. And a lot of that was the indirect costs of mental illness on society. In fact, the number one category of problem wasn't diabetes or heart disease or obesity. It was actually mental illness and depression, particularly that was debilitating people in such a way that made them not able to live their lives. And so if there's this new treatment out there that has success rates that, you know, are double, triple, or even more the conventional therapies, it's sort of a big, it's big news. It's like, wow, we discovered the cure for cancer or something, you know, and I don't want to overstate it, but I do see these results and I

see it in clients who've used it. I've been reading the literature. Can you highlight some of the important studies that have sort of documented this and their comparative value to, for example, traditional psychiatric treatments? Yeah, well. You sort of briefly mentioned the one, but I wanted to. Yeah, you talked about depression already. And what we know with our medications or SSRIs, you know, they're hovering, depending, if you bring in all the negative studies that weren't published, they're hovering right around placebo.

And we're not seeing that. I mean, there's certainly. Hovering around placebo. I like that. That mean, there's certainly. Covering around placebo. I like that. That means like not effective. Well, it's really the doctors. It's that therapeutic relationship that's bringing it. But I mean, like the big picture is like stepping back versus a caveat is like these are not

cure-alls. Like that's not. But like for the SSRIs, there are certainly a portion of the population that respond well to them. And I think that's, you know, that's what we really need to acknowledge. Like some of these medicines are life-saving for people and I don't want to throw them out at all. Like they, they're for the people that respond to SSRIs or SNRIs or other medications, they're fantastic, but there's so many people that don't respond to them. And so for those people, when we start looking at, you know, like a psilocybin session, or a ketamine session done really well

in a therapeutic container, or MDMA, you know, we're seeing the reason that like you said, the fundamental, the foundation that is causing, you know, those other symptoms, and it's very rarely just depression, it's often depression, it's very rarely just depression. It's often depression. It's often depression and anxiety. It's often substance use or other self-soothing behaviors, you know, sex, eating, smoking. There's other self-soothing behaviors that are completely logical for people trying to feel better. And, you know, the psilocybin studies and the psilocybin studies. And the caveat here is, remember, the psilocybin studies are on the synthetic psilocybin. The majority of the clinical trials have been done with the synthetic.

So we actually haven't even seen the clinical trials of how good it will be with the whole mushrooms. So we have this really interesting situation, Mark, in that all the clinical trials, other than a few now, are all using synthetic psilocybin. And all the people out there that are having a psilocybin mushroom session in the real world are using psilocybin mushrooms. So we have a bit of a disconnect. So we don't even have the clinical trials that are actually looking at the psilocybin mushroom, which have many more constituents in them than just the synthetic. You know, you have Balecystin, nor Balecystin, nor Silicin, Silicin, and many other constituents.

So I think that's an exciting place there is what kind of results are we going to get around depression when we can actually really do good studies with the whole mushroom. And what we're seeing, like, for instance, in our program, we have an end-of-life, so Roots to Thrive, we have an end-of-life cohort, and that's what we work with, that go through. And their depression scores at the beginning to the end are clinically, you know, six or seven points better, which is a huge difference. Yeah.

Is this the Hamilton Depression Scale? We mostly use the PHQ-9. We try to use something that's shorter and smaller because we are working with people that have end-of-life distress and we don't want them to be doing a ton of long questionnaires. But yeah. And these are standardized research-validated questionnaires that researchers use to actually measure the effectiveness of interventions for depression. So I think this is, you know, when you see a big, it doesn't sound like six or seven points a lot, but it is actually a big delta on the improvement in depression. Yeah, that's a huge, I mean, a lot of the medications are just looking for two to three points.

And that's considered a success. And we're seeing six to seven, double that in considered a success and we're seeing six to seven double that in these studies so we're seeing quite a bit but but it goes really back again to what you said earlier it's like we're hitting the foundations we're hitting the root trauma we're hitting that thing that they've been carrying their whole life you know that has really influenced their mood you know that so often like this human these human conditions that so many people have i'm not good enough you know i don't belong my parents didn't love me you know all these things that just you know sit at the

base of our our wellness and is you know when you extrapolate it out it's the reason like again back to gabar mate why we see addiction or why we see other self-soothing behaviors or anxiety or depression, et cetera. It's sort of a soul crisis, in a sense, in our society where we're all sort of living in worlds where we're disconnected from our original ways of living as human beings, close to the earth, in concert with nature, know eating real food in deep community and tribal networks we're isolated we're disconnected we're disjointed we have social media but it's anything but social sorry anti-social media and uh it's very destructive more disconnected more isolated and you know i remember you know you know as a young man i i had the chance to take psilocybin mushrooms, magic mushrooms in college. And I think we had some big doses because now they talk about hero's doses and I've tried it. And it's not anything close to what we did in college.

And I remember this feeling of really having a profound sense of connection with nature and with the friends that I was with in those moments. And sort of a dissolving of the sense of separateness, which is sort of at the root of depression, right? It's this sense of disconnection, isolation, meaninglessness, hopelessness. And these compounds somehow change our brains in the short term to actually dissolve some of this sense of separateness and isolation and disconnection, which gives us so much of our existential suffering. So can you explain the science behind how that might work and what the theories are behind it? I know there's been a lot of talk about, for example, the default mode network and the dissolution of the ego and ego death and all these sort of terms, which I don't know if people understand what they mean, but can you talk about

from a scientific perspective, you know, what actually may be happening and how this works to sort of change people's sense of relationship to themselves, to others, to the earth, to nature, to humanity after they take one of these compounds. Yeah. Well, and that's such a big question mark. So not question mark, but question mark. It's like, so first off, we have tons of theories, right? We have tons of theories on the mechanism of action of all these medicines.

Like which receptors do they bind with? and what is the downstream response to that which neurotransmitters are released you know so we're looking at a lot of things so we've got the classic psychedelics like lsd and psilocybin we've got psychedelic light but i i would argue is very psychedelic like ketamine and then like mdma which is a pathogenic and how how they all work. And so, you know, there's some common threads that you see. So I'm just going to try to weave them a little bit together, but not perfectly. You know, so there's this one part where we do know that for people that are in like a PTSD response, you know, their amygdala is kind of running the show. And so we see that with like stuff like MDMA, we see the amygdala is kind of running the show and so we see that with like stuff like MDMA we see the amygdala gets this calm down and then more active like the prefrontal cortex we so that you get into

this parasympathetic Dr. Julia Holland is excellent at really talking about getting into the parasympathetic and where you can really just be calm and thoughtful and not having the alarm bells running your life and so there's that one element there that it gets us calmed down so we can then think and be. There's other theories that work around, you know, getting- So just to recap that for people, basically there's a part of your brain that's the old reptile brain, the lizard brain that's fight or flight or freeze.

And that's the sort of limbic brain or where the amygdala is, which is the sort of, you know, fear center in the brainala is, which is the sort of fear center in the brain. And the frontal lobe is more the adult in the room, the grown up, the person who has perspective and in charge of executive function and can kind of sense the world in a more accurate way. And often they're disconnected in our modern life. And the amygdala is activated. The frontal lobebes decrease in function and there's an interesting actually theory about this that that people who are inflamed which by the way is most of the people today in the western world who are eating a processed american diet that the inflammation the brain disconnects the frontal lobe and the amygdala so it activates this increased

sense of disconnection isolation fear uh you know otherness, divisiveness that we see today in society. So I think healing our brains is an interesting perspective to think about. How do we use these compounds to potentially not just mask or treat or cover symptoms, but how do we heal our brains using these medicines and the therapies associated with them? Yeah. And knowing that we do need our amygdala, right? Like if we're under that we do need our amygdala, right? Like if we're under attack, you need your amygdala. You need to be like in that dinosaur brain for sure. And, but you can't run around every day in that space and be healthy.

So certainly, and then there's this other part of the psychedelics that, you know, they're that, and this is where you see the connectogram that Beckley Institute, you know, funded where you see that connectogram, like this is your brain, not on psilocybin, this is your brain on psilocybin. Many people who have seen that is, is that there's this, you know, this part that there's parts of our brains that just don't talk most of the time. And under the influence of these psychedelics is that those parts of the brain then connect. And that gives us a possibility of having new ways of knowing, new ways of interpreting. And that's part of the theory of ketamine too, is that part of the influence of ketamine on the brain is that, you know,

you get these repetitive pathways, these super highways, and you know, the brain always wants to go to the easiest way. That's why, you know, the first time you drive, it's impossible. But now when you drive, you're not even thinking the brain has found all these super highways of driving that you don't even have to think about. But so it does allow now that so you have the super highway of anxiety, or depression, and that's where you go to. And then suddenly, you now have this new way of going, oh, and I don't have to do that. And you open up a new pathway. And with practice, that pathway can stay and you open up a new pathway and with practice that pathway can stay and you can continue with that neuroplasticity and so that is another

one of the theories and and then there's also like you know like track b has come on you know and a lot of people say oh now it's a it's a receptor of the day but but it also makes sense you know are we getting new neurons like where is that neuroplasticity coming from? Where is the BDNF coming from? And why are we getting it with different ones? And there's the serotonin receptors that are binded with. Then we're talking about the neurotransmitters. So we're getting like with MDMA, we're talking about more oxytocin,

possibly more dopamine, possibly more norepinephrine. And so, you know, I think like your question is, is why are they working? And my thing is like we have a lot of theories and these theories are going to continue to proceed. But they all make sense to me. Like there's, you know, know with ketamine there's like the theory of a that we have a glutaminergic surge and maybe that's why we get such a rapid antidepressant effect like think about it the ssris we we tell our patients oh maybe in six weeks you'll start to feel better yeah but on ketamine like literally an hour later, people are like, I feel great. Yeah. Yeah. So I'm not answering your

question as well as I think you want it to be answered. But I think there's a part of this that is like, we have a lot of theories. They make a lot of sense. And I don't think we're smart enough yet to have really hit the pinnacle of why these work. Because then you also have this other part of the brain that you've experienced, that we've experienced. We've all like everyone that has done psychedelics and had that big, ah, universal consciousness, universal oneness. And then like, what is that on top of all these other things? And I sometimes just feel like we're just not quite smart enough to fully appreciate all those mechanisms. Hey there, it's Dr. Mark.

When it comes to maintaining my health, there's one essential element I never compromise on, red light therapy. It's become a crucial part of my daily routine and let me tell you why. By absorbing red light through our skin, our cells receive a boost in energy production, resulting in many proven benefits such as reduced pain, inflammation, healthier skin, faster recovery, and lots more. Unfortunately, our modern indoor lifestyles and seasonal weather changes like fall and winter often limit our exposure to this vital light source. And that's why I've relied on Juve for years to provide me with the healthy red light exposure I need to support optimal cellular function. What I love about Juve is their patented modular design.

It offers a variety of setup options to fit your needs. Plus, the treatments are incredibly simple and can be completed in as little as 10 minutes. All you have to do is sit back, relax, and let your body soak in the rejuvenating light. If you're ready to get a Juve today, you're in luck because Juve's biggest Black Friday sale is here.

Juve is offering incredible once-a-year savings of up to $1,300 on a brand new Juve system, including their popular Juve Solo, now $250 off. But act fast because this amazing sale ends Cyber Monday, November 27th. Visit juve.com forward slash pharmacy to take advantage of the unbeatable Black Friday deals. That's J-O-O-V-E dot com forward slash pharmacy F-A-R-M-A-C-Y. And don't miss out on this limited time offer. The sale ends November 27th.

I want to tell you about a new superfood that seems almost too good to be true. It has thousands of five-star reviews and life-changing testimonials from users, and its benefits reach almost every area and every system of your body. I'm talking about Armra Colostrum. Colostrum is the first nutrition we receive in life and it contains all the essential nutrients our bodies need to thrive. Armra harnesses the superfood to provide you with a host of research-backed health benefits like supporting nutrient absorption, healthy blood sugar levels, and fat burning. And it's even been shown to

improve endurance and build lean muscle mass. So whether you're looking to strengthen your gut, increase fitness performance and recovery, or simply experience the incredible benefits for aging and longevity, Armra Colostrum is the real deal. We've worked out a special offer for my audience. Receive 15% off your first order. Go to tryarmra.com forward slash mark or enter mark to get 15% off your first order. That's tryarmra.com forward slash mark. T-R-Y-A-R-M-R-A.com forward slash mark.

And now let's get back to this week's episode of The Doctor's Pharmacy. What I was most excited talking to you about was your clinical experience, because I've had a bunch of people on the podcast talking about psychedelic therapy from a research perspective or from a more cultural perspective, like Michael Pollan and Tony Bossis and others talking about psychedelic therapy, about Ibogaine, Deborah Mash, they're researchers. You're a doctor and you treat patients. And I'd love to hear some of the work you've done, both end of life work, but also around depression and what you're seeing on a clinical basis and the stories of your patients, what are the, some of the cases, obviously not using names, but you know, what are the stories that you see and how does, how does this work? And tell us about the process. If someone sort of, let's say this is,

gets legalized in a year or two or whatever, what are we looking forward to as sort of the standard of care? And I know you're very rigorous about how you do this. There's a lot of pre-work, there's the therapy, there's the post-work. It's not like just go in a room and take the drug and put a blindfold on and put some nice music on and we'll see you later. It's like, it's a very structured process for working people through their experience of mental challenges and their traumas and end of life experiences. So let me just share some of your actually real world experiences, both, you know, around psilocybin and other compounds they've used in different conditions. Well, Roots to Thrive is a nonprofit that we've, a bunch of healthcare

providers came together and created a program and said, we need to do this. We need to make this happen. So we built it on the scaffolding of ketamine-assisted therapy. And what we did is we knew we needed to create a really strong container. And what we didn't want to just do is we didn't want to just be in the biomedical Western way. Like we could see the work that was coming out of the clinical trials. But we all have the privilege of working in a part of Canada that has a really strong Indigenous heritage and way of knowing. And we have Indigenous elders on our team who, right from the beginning, you know, brought us through the process of creating a very ceremonial container. Something more of this, what's called two-eyed seeing. So taking the best of Indigenous ways of knowing and taking the best of Western ways of knowing and weaving them together to make an even better synergistic

container. And so our process is very rigorous. Our programs run over eight to 12 weeks. We do an incredibly detailed intake to make sure people are psychologically safe, that they're medically safe to work with the medicine. So whether psilocybin, MDMA, or ketamine. And because we're in Canada, we're in this position where we can actually get exemptions from Health Canada to work with psilocybin and MDMA. So that's why those are part of our program. And then ketamine, of course, is a legal medicine that we've always had access to. And so we have a very rigorous intake. We really make sure that the people we're working with understand what they're in for and really solid consent.

And everything we do is in group. And we know that people like we've already talked about crave community. They need community. We need connection. We need love. We need unconditional positive regard. We need to be witnessed and heard. And that's the container we're making. We're making a whole human container where people can show up as participants, as their full self, and so can the therapy team get to show up fully. And the team is very interdisciplinary. So we have medical doctors working side by side with nurses, with therapists, with indigenous elders, with somatic therapists, with energy workers, clinical counselors, social workers, all of us working together in a non-hierarchical way to serve the patients. And so there's a really detailed preparation and getting and starting the integration right away. And so good in fact, Mark,

that we start to see people's anxiety scores already dropped before they even get to the psychedelic session. We see their depression scores dropping before we see their substance use dropping before they get to their first psychedelic session. And then they come on site together. So all this is done virtual, which is really interesting, because we didn't think that would happen that we didn't think people would bond so well virtually, but they do they bond really well. And then they all come together on site. And when they come when the participants are coming together and meeting for the first time, it's like family and friends like reconnecting.

It's like they've known each other forever and they really only known each other for four weeks. The ceremony on the day of their psychedelic session is very, it's very ceremonial. It's you know, the setting is set, the safety consent. It's a beautiful room. We make sure people can share their intentions and their pillars of strength and the kind of support they need. And then the whole team holds a ceremony.

So the medicine is, everybody has their medicine together. In the case of psilocybin, they're ingesting it. MDMA, they're ingesting it. And ketamine, it's an injection. But all the participants get the medicine together. They wear eye masks. They have a specially curated song list that's just for the group. And then they journey together. And then as they emerge out of the medicine, they start their integration and their sharing in community. And so that is such a healing, healing way. So our whole team used to work in the dyad model.

And now we all work in the dyad model. And now we all work in this team model, in this group model, and no one would go back. They were just like, this is amazing to watch these participants. They hear each other. They share the stories. They hold each other accountable. And the healing, I think, is just doubles, triples than what it would in our old model of doing the diet. And then they continue to integrate.

And we see success rates of PTSD resolution of like 92% in 12 weeks. Wow. So what is the typical PTSD resolution in traditional psychiatric care? 30, 40% over many, many years. So treating people for years or decades, you see maybe a 30% resolution. And you're talking about 98% resolution? 92% in about 12 weeks. In 12 weeks, yeah. Wow.

The results that we're getting with our 12-week program are very similar to what we're seeing with the MDMA. So there's something that's very similar on this, this whole process of bringing people together, preparing three sessions, good integration, and that time. So it's not just the medicine that does that. It's this therapeutic alliance as well. And so, and, you know, in our program, we, again, it's like we need connection. We need to connect with people. And so much of mental health issues is about we're siloing.

We're like, I'm the only one with depression. I'm the only one with a needing disorder. I'm the only one with this. And then you have these groups coming together. And I think this is part of the success you see in stuff like AA and NA. It's people coming together in community with this shared experience. But here you have people having this shared psychedelic experience.

But even in AA, the success rates are in the 10%, maybe 20% rate. It's not very effective. It's better than anything else, but it's still terrible. And what you're seeing here is just orders of magnitude different. And I think it gives me a lot of hope for where we're headed with this.

And I mean, tell us, tell us a little bit more about some of the personal experiences that you've seen people go through and, you know, stories of transformation from traumas and depression and things that you, you've seen around the work you've done. Well, there's kind of two sets here that I'd like to share with you, Mark. So one is like, we have our psilocybin end of life group. So we have right now we have 13 people going through a program going that have

just started the program. Again, we've just gotten more exemptions for that from Health Canada. But what's so remarkable is people are to qualify, they have to have an end of life diagnosis. And, you know, most of the people that have come through our program actually all of them probably at this point you know really in based on their prognosis should have passed by now and only a few have like only three out of the 40 some how this is going to affect their family. And now they're living. They're out there living. They're going surfing.

They're going camping. They're going on these vacations um one of our participants uh you know walked in with two canes like just barely being able to walk and at the end jumped up off cane under arm walked out and was and was thinking you know i think i might go back to work i might i really miss work i think i might go back you know there, there's, there's this, this whole, these layers that just get lifted and are gone. And so we were seeing that in the end of life. So they get to come together under this shared issue that they've been given a palliative care diagnosis. And they get to talk about it openly and honestly in a group, like that's the community

part. And then they get to journey and have this shared experience, even though they're having their individual experience, they're also having a shared experience. And then they have this community to talk about it, that truly, truly understand it. So we're seeing that, you know, this, this longevity, and also this whole removal of layers of depression and anxiety related to that diagnosis. So it's absolutely a delight to be able to see these people like get their, their ability to be connected back to their families and their friends and their life, even though they do have this palliative. They're living more even while they're dying. Exactly. And are you seeing any differences in the survival rates of these patients? Well, the thing is, they're all still alive. Other than, like I said, three. And one chose MAID and decided, wanted to go out on their own terms. And that was totally fine.

And then two others. That's euthanasia, which is legal in Canada. Yeah, yeah, yeah. Medical assistance in dying, right? Correct. Yeah. Yeah. And so just people being able to go out on their own

terms while the rest are still you know they still have the challenges of the palliative care diagnosis they still have bad days but they still have the more of the ability to have those just that those layers of of depression and anxiety just lifted and not as why haven't they died is it is it just because the study duration is not long enough for them to have kind of reached the end of their life? Or is this psychedelic medicine somehow helping them survive longer? I mean, there's been evidence that different kinds of therapeutic mushrooms are effective in cancer.

But I'm curious about any data you have about that. Well, I wonder if, you know, like you think about the neural inflammation related to anxiety and depression right and and not you know wake waking up with dread or waking up with with you know just that heaviness of knowing and then that's lifted you know like there's this i that's where I would go. I would go like they, they, all this other stuff is lifted and now the body can, can move forward in these other biological processes. If you're not depressed, you don't have that, that inflammation of being depressed, that inflammation of being in anxiety. I mean, I, I don't know.

It's, it's a bit of, it's a bit of awe and wonder for us as well as the team to get to watch people get this and and what what you know what are the biomarkers that we'll find in these people that are doing well and we continue to follow them and in fact some of them have come back and we have an alumni program and i think that's a really important element like yes what is what is what is they haven't died i had this patient once who was in hospice but he was was in hospital for five years. He just didn't die. He had stage four lung cancer. I was like, what?

People just don't follow the typical norms. And I just wonder, you always say the biggest pharmacy is the one between your ears. And so who knows what is being released when you kind of relieve that existential stress and fear and connect to love. And, you know, interesting. Yeah. Yeah. And what is happening? Like, we don't know. And we follow them.

We follow them out and see, right? And we'll find out hopefully over time. And maybe, you know, but that's what I was going to say about the program. Like, what is really important is that once people are in the program, we're like, you're in the program as long as you want. So even though the 12 weeks

is the end of the official program, if people want to come back and do so, we have people coming that are a lot of psilocybin alumni, palliative care people that are coming back for their third psilocybin session, because they're doing well, and they're taking it to the next level. They're going, you know, now I want to be a better dad. You know, now I really want to work on this other stuff, because I'm not worried about my cancer anymore. What I'm worrying about is preparing relationships in my family. And so that's what we see on the psilocybin side.

And then on the other side, we have this very ceremonial ketamine assisted therapy program. And so that really caters a lot more to health care, like frontline health care workers and first responders. And, you know, you ask, like, what are some of the success stories? Like I remember one of our, one of our MD colleagues who came through the program. I mean, he was, he was having recurrent nightmares over an episode in the ER, recurrent every single day, nightmares, same night. First psychedelic assisted ketamine session in his small group of eight people. Next day, the nightmares are gone. Wow. You know, just like that. And we see

that with our firefighters. We have a lot of firefighters that come through our program, police officers, paramedics, doctors, nurses, and similar things. You know, I was always on high alert. I always had to sit in the restaurant in the chair where I could see all the exits and all the doors. I went out for dinner last week. Didn't have to do that. You know, letters from the spouses. I've got my partner back. Letters from the kids.

My dad is, you know, there's these, all these layers like we, and especially in, in these caring professions and these first line professions, like, you know, there's, there's these,

I think, I think everybody that gets accepted to these professions and medical schools should have to do psychedelics first. Right. Because there's something about us that we drive, right. There's something, why are we so driven to do these things? Like, and I think it's ubiquitous.

Like it's, I'm not good enough. If only I accomplished this, then I'll be important. Or I can earn my parents' love. Or, you know, there's lots of things that are so common. Imposter syndrome, all these things. And especially in the first responders, you know, this white knight syndrome, I'm going to save people, you know, I couldn't save my mom from being beaten up. So I'll go out in the world and I'll save other people from house fires or, you know, stuff like that.

And if we could really help people cure that when they get hired or accepted into these, first and foremost, I just imagine how much more resilient and healthy they would be in these programs. But you take that trauma and then you layer on seeing people hurt, injured, not being able to save someone, you know, and you layer on all these traumas and then you take those off. Like they get, they're able to get to the seat of that trauma in their psychedelic journey

where they can go, yeah, that happened. I did my best. And it's not happening now. Powerful, powerful. So, so, you know, this is, you're talking about right now is using, you know, full dose psychedelics as part of a structured therapy, but there's also this whole movement of microdosing, which you're involved with. And actually, you're one of the co-investigators of a really remarkable study that's a community-based study as opposed to a sort of a clinical study in an academic center with over 25,000 people, which is a huge study. And you're able to use an app to help track the behaviors, habits, responses, outcomes of people who are using microdosing. Now it's all over the place in terms of what they're using, where they get it from, how much the dose is. But I'm just sort of curious about, you know, what you're seeing from this data

because, you know, one thing is to take a, you know, a psychedelic journey where you have really clear changes in your perception, your feeling, how your body feels. The microdosing is sub-perceptual. You don't necessarily know you're doing it. So, you feeling, how your body feels. The microdosing is sub-perceptual. You don't necessarily know you're doing it. So, you know, can you talk about some of the data? Because it seems really quite fascinating, this having different effects on the body, and it's also working in similar ways, but it actually might be a strategy for helping people as a kind of long-term therapy, not continuous therapy. We can talk about why, but intermittent therapy to actually help with some of the same issues. Yeah. And the, the,

the driving force behind this study Mark was that we knew like we had hundreds and like really closer to thousands of case reports of people microdosing. And how do you, how do you even begin to look at that? So it's a prospective observational study. So it is a registered registered clinical trials. And what we wanted to do is figure out where where are the signals. So amongst all the reasons that people were microdosing, are they getting the results that they think they are? And so, you know, we, we had people as people come into the study, you know, we get the demographics, they get all the reasons why they're microdosing or why they

hope to microdose, we have all the validated scores. So all the mental health scores that we can put in an app, we have validated tests for reaction time and memory. And, and then all and then all the different permutations of what people are microdosing. So are they microdosing psilocybin, LSD, ayahuasca, wachuma, like all everything and what they're stacking it with and what they're putting in there. And, you know, some of the remarkable, we've already published a couple times,

twice in Nature Scientific Reports and what we found like in those publications and we're still crunching, like we still have eight teams crunching data on this that's continually coming in. But we found like, you know, positive moods go up, low moods go down, depression goes down, anxiety goes down, reaction time gets faster in 55-year-olds that are stacking psilocybin with niacin in lion's mane. And then there's a lot of other

things. So when we first launched the study, we kind of had like a sort of an idea of why people were microdosing. And then as it launched, we started having all these other groups come to us and say, hey, what about us? We're also microdosing. You know, like there's this group of 30,000 women, moms who microdose out there that are like part of this complete support group that are microdosing for multiple reasons like premenstrual dysphoria, menstrual challenges that maybe don't qualify for something as severe as PMDD, you know, cramps, migraines related to menstrual, stuff around depression, postpartum depression, and a whole bunch of stuff there. There's a whole bunch of neurological challenges. So people that have these progressive neurological conditions like Alzheimer's, Parkinson's, cerebellar ataxia, you know, are out there and we're seeing

improvements in that. And all of these, of course, have to be, we have to take these to clinical trials to confirm. But when you have 25,000 people, you get to start to see where the signals are. You get to see like in which group, in which type of microdosing, on what kind of schedule is getting a result. And it's kind of this thing that people are microdosing for so many things. It's over the top. You know, some people are microdosing to have more energy. Some people are microdosing to have less energy, you know, and definitely every single mental health condition is being microdosed for

out there. We have elite athletes that are microdosing to improve their reaction time, to improve their focus, and on all sorts of regimes. So what it's going to pan out to be in the end, I think what we're going to see is we're going to see a whole bunch. And based on what we're already seeing, we're going to see, you know, certain people are going to microdose maybe three or four times a month, just when they need to. Some people are going to microdose on a very rigorous schedule. We see that already. We see a whole group of people that are using microdosing to

slowly wean themselves off of other medications that they don't want to be on anymore and kind of doing a cross wean. And then we see like this, this neurological data, which is I find the most impressive because we have so many progressive neurological degenerative conditions. And if we can find a way where we can challenge ourselves while we're taking these medicines that can help with neuroplasticity or stimulating new neural pathways, then we might be finding something that's really going to help. I mean, we're all progressing that way. And I would love to keep my brain online as long as possible.

Is this like a potentially a preventive treatment for Alzheimer's or for Parkinson's? Or, you know, because you're seeing, you know, signals that show that it may be improving some of the symptoms of it or reversing some of them, which is fascinating, right? And working on so many different parts of the brain, like you think about like, you know, proprioception

and people are getting better in their proprioception. So their ability to balance and move their body in space and time and, you know, tensegrity, like, you know, people being able to say, like, ever since I started this, I, you know, my surfing has gone through the roof or, you know, maybe it has nothing to do with it. But it's really, I mean, if you're an observational scientist and you're really curious, you have to be going like, why? You know, like, why is this? Why? Why in so many different areas are we seeing people? And maybe it is, you know, partially expectancy, but maybe there's something more to it. Because I think there's some things that you just can't have expectancy effect for.

Like I don't think in something like cerebellar ataxia, you can expect that a microdose will help with that. Right, right. It's a degenerative condition. Yeah. That's a condition where you kind of don't have balance in the part of your brain that is in charge of balance and walking and normal movements is all messed up. And so, yeah, you wouldn't expect something like that right someone has a stroke or some physical deficit to see an improvement but it seems like we're seeing changes so i think it's a whole area of additional research and i can you know i know your your partner uh has been paul stamets is actually

working uh with you on this and theamets stack as a way of actually researching this and there's a you know um I think it's called MycoMedica which is a company that you've informed to actually help deliver this therapy at scale and do the research behind it and I think it's very impressive um in in are you seeing people like get the relief from depression with with microdosing and anxiety in the same way that you see? That's what caught my attention first, Mark. Like over 10 years ago, I had three patients, like literally in a very short timeframe, that were depressed and suicidal. And that's what they came in and said, this has changed my life.

I need to tell you about it. Just microdosing, not actually full dose. No, just microdosing. Just started taking little bits, taking a little bite of a mushroom every day and saying it's changed me. And that's really what piqued my interest. That's where I started collecting the case reports

and really diving into what Jim Vadiman had been doing because he had really been collecting case reports for much longer. And this just started looking at that nuts. So, yeah, and tons of case reports now. And, of course, this will bear out is with people that have written up their protocol on how they are slowly weaning themselves off their SSRIs. So very, very like high, highly educated people. Like this is not, you know, so often in medicine, we say, oh, well, you know, people are susceptible to all this. Like these are people that are super smart that take control of their health and they're sitting there going, okay, here's my regime. I'm microdosing a little bit. And as I get that stability, then I wean down on my SSRI a tiny bit and I keep my microdosing and they're

doing it very thoughtfully. And we're seeing a big difference here. And the nice thing is that it gives them the ability to dose themselves as they need to. So when their mood is solid, they're not microdosing. And then when they start to feel the mood dip, they'll start to microdose again. So there's this kind of, and we don't do that with medicines, right? We're just like, no, take the pill every day. And so, you know, we may have to think

a little bit differently because maybe people don't need something every single day. But definitely seeing improvement in depression, definitely seeing improvement in anxiety. Are you, are you seeing, you know, more advanced thinking in Canada around this in terms of legalization pathways for therapy? I mean, with Roots to Thrive, you're able to now legally do this with people who are at end of life as a life as a legitimate reimbursed medical therapy, right? Well, we hope so. We're working a lot with Health Canada.

We meet with them regularly and really, you know, just like the FDA, Health Canada, they want clinical trials. They want lots and lots of clinical trials. And we're trying to bridge it both. And this is where Roots to Thrive really does it well, is that we are studying real people in real programs and getting real outcomes. Most of our patients wouldn't get into clinical trials. So are we seeing more openness in Canada? I think we're seeing, you know, researchers at every single university are leaning in to doing this research. We have the program at Vancouver Island University with, you know, outstanding amount of applications of medical professionals who want to be trained in these therapies.

So you kind of see that the practitioner is a little bit ahead of the regulation. We have an eight, we've, we've had two national polls in Canada on psilocybin with six, with 80% of Canadians supporting the use of psilocybin, especially at end of life. Wow. You know, so that's, that's a,

that's a higher rate mark than we had support for cannabis when we legalized cannabis federally in Canada. So more people right now support psilocybin than supported cannabis at the time. So that's pretty high. Yeah. And we see the colleges, the medical colleges and the provinces that administer health care trying to figure out how to do this. And so we're in this weird situation in that these medicines are available everywhere.

Like you can go into Vancouver right now into like 10 different stores and buy psilocybin. You mean it's legal to buy? It's decriminalized in Vancouver. It's decriminalized in two other cities in Canada. So people can just walk into the store. There's dispensaries like a cannabis dispensary in canada wow yeah so that's different what is one thing being decriminalized another

thing being legal to sell so well well in decriminalize it just means it's the lowest police uh priority so they have to have solved every other crime before they can go after the dispensary yeah basically so it's de facto it's de facto legalized. And so what we're seeing is a huge underground, um, like happening with, with psilocybin in Canada and, and MDMA has been decriminalized in British Columbia as well. And so people have access to it, but the, the issue is, is that medical professionals are limited. Limited in what they can do or how they can do it. We have to get special access.

We have to apply for each and every patient individually to Health Canada to get a yes to do that. So you can imagine. I mean, these medications have very low toxicity and very low you know sort of adverse effects um not not without adverse effects because i think in an unsupervised way or in the wrong setting it can be very destabilizing for people i mean the whole conversation on set and setting is important which is you know where do you take it what is the setting and and and how is it the overall experience you know if you're in a time square versus a you know a quiet meditative temple somewhere it's a very different experience being on a substance that alters your perception

and your sense of safety. So are you feeling like that this sort of is premature to allow it to be available, you know, in dispensaries around Canada? Do you think that's something that actually could be helpful in bringing about its sort of better use within therapeutic settings or do you think i think it's it's kind of a problem well i'm torn mark because every one of us that have had a psychedelic experience have had it in the underground for the most part like in our teens our young adults with our last week whoever right like so i'm corn because i want safety for my patients i want them to have the best set. I want them to make sure that this is not a medication that will destabilize them or this is an experience that will destabilize

them. I want a strong team around them of support. And I also want the freedom for patients to have that in multiple settings. So if they want to have it in something that's completely hospitalized and completely medicalized, I want people to have that choice. And if they want to have it in a completely beautiful outdoor setting in a beautiful retreat center, I want them to have that choice too. And if they want to have something in between, I want them to have that choice. And I think the only way we're going to get there is if we legalize and then put parameters around that in some way. So to make sure that psilocybin that's being provided or people are getting is really, in fact, the highest quality without bacterial contamination.

And if they're doing MDMA, that it's been CGMP created, meaning good manufacturing practices. If people are going to take the time to work with these medicines, created and meaning like good manufacturing practices like that it's about i want if people are going to take the time to work with these medicines i want them to have the best possible outcome and if it's a contraindication that they shouldn't be having it then there needs to be a process of them going through that and that's our concern is we often are rescuing people out of the emergencies that have worked with people that don't have any kind of medical clearance background in the underground. And that's not disparaging people that work in the underground. It's just saying that we need this high quality intake to make

sure people are psychologically appropriate to work with it, that they're medically appropriate to work with it and then the best setting for that five star all the way and right now what we kind of have is we have this two-tiered system if you have a lot of money you can go off to a beautiful retreat center somewhere where it's legal and have a beautiful session and if you don't have that that kind of those resources then you're you know you may be working in a place where you're going and buying something that you don't know if it's what the quality is of it or. Yeah. And so I'm torn, you know, so the legalization hopefully pushes it so that we can have high quality therapy. And I think it's necessary.

I think people have the right to their own consciousness. I think people have the right to their own consciousness. I think people have the right to these substances. And, like, the fact that a mushroom is illegal right now just is mind-boggling. It's mind-boggling to me. Yeah. I mean, it's considered when alcohol is legal and tobacco is legal, which are really highly addictive, destructive substances. And these aren't, you know.

Yeah. Yeah. Yeah. And we need to move past this. I mean, this is propaganda. Like this, we're in this place because of propaganda,

because of stigma. Right. And I think we should be as physicians, we should be really angry that these medicines were taken away from our patients. You know, we're, we're 40,

50 years behind where we could be, you know, this, we could be in such a better situation right now. And we have such a, you know, a could be in such a better situation right now and we have such a you know a crisis here of mental health a crisis here of substance use and it all comes back to trauma and connection and love but trauma connection love healing trauma building connection and kind of leading with love i think that's powerfully beautiful you know where do you see us

in a year three five years in in healthcare with this in Canada? And maybe in the States, you have some insights. You spend a lot of time here. Where do you see this going? I mean, you think this is going to completely change psychiatric medicine? Do you think it's going to be still sort of marginalized with big pharma pushing pharmaceuticals? I think we're going to see everything. I think we're going to see some provinces in Canada and some states in the USA really lead the way. They're going to make

mistakes. We're all going to make mistakes. That's a given we're humans. And but we're going to hopefully each state as each state comes on board in the US, we're going to see it done a little bit better, a little bit more thoughtfully learning from the others, you know, Oregon sticking, it's not going to leading the way here. And you they're not doing it perfectly but they're at least they've started and i give them a lot of grace and compassion that way and go way to go like that's great you know washington many other places are following many other cities are legalizing and i that's what i that's what i see is one after the other i think this is a non-isan issue. I think people need healing. We want to feel better.

We want to feel more connected. We want to be happier. We want to have more joy. We want more safety. And this is a way, that way. I see, and what I see, like, there's no doubt there's going to be pharmacolization of this.

No doubt that is going to happen. And- Pharm is going to take it over, you think? Is that what you're saying? Well, no, I don't think they're going to take it over. I think this is my hope. This is my hope for the world is that what we see is this whole circle, a circle of availability, that certainly there is this level that is like pure pharmaceutical.

You're going to need that. There's going to be people that want the pill, that want, I want to know exactly what the dose is. I want you to tell me exactly when to take it how often to take it and i don't i don't see a problem with that and i also love the other side of it like the circle of it that can you do it in a ceremonial setting can you do it in a more spiritual nourishing setting a more culturally appropriate setting and and everything in between. I don't think it's an either or. I think it's an and. I think that whole possibility is there. And I think we have the right to choose where on that circle do you want to access these medicines if you want to.

That's really my hope. I hope that we have enough foresight to see that these are, we as humans seek non-ordinary states, we seek homeostasis, we seek to heal, we seek to feel better, we seek to be connected, and we have the right to do that. And however we do that, I don't think there's any monopoly on it. And I think we should push very hard on any kind of monopoly and just say it's an and. It's this and this and this and this. Yeah, I mean, you know, when we see, you know, the ailment, not just of individuals, but of society today with the increasing divisions and hatred and tribalism and, you know, nationalism, otherism, you know, it seems like this may be a tool to help heal that divide and kind of repair our humanity, which is now fractured in ways that I don't remember seeing in my lifetime. And, you know, we were recently together at a dead show in Washington, and it was just an amazing experience, you know, about 30,000 people,

you know, probably from all walks of life, from all different political persuasions, from all different beliefs, from all different religions, from all different cultural backgrounds. And yet we're all there sharing this one common experience of enjoying the music, being in nature, dancing and having a great time. And, you know, people were kind to each other, polite to each other, nice to each other, help each other, you know, it's part of the dead culture in a way, but it's like, it's like, wow, I just kind of occurred to me, wow, we just, you know, we need things that bring us together rather than take us apart. And music certainly does that. But, but these medicines seem to be, you know, such a unique thing from my perspective in the history of medicine.

There really isn't anything akin to it from a pharmacological perspective or therapeutic perspective. When people have these shared experiences, exactly like you're saying, we become together. We appreciate our commonalities and we just let go of the things that are different. We agree to agree and not worry about where we don't, where we don't. And, you know, you asked earlier about some of the things that really stand out in the therapies. And one of the ones that really stands out is we had a First Nation woman who came through the program. And, you know, she said. That's what they called Native Americans in Canada, you know, she, she said.

That's what they called Native Americans in Canada. First nation. People would say, what is that? Yeah. First nation or indigenous. My friends prefer first nations. And she said, you know, I was in this group, this small group in Roots to Thrive. And I looked around and all I was, everybody else was white. And I thought, how the hell am I going to heal with all these white people? And then she goes, and then, you know, this was like, you know, 16 weeks after the program had ended. And she goes, you know, then I realized that's the only way we're all going to heal

is together. And, and this woman is now on our team. She's joined the team and she's phenomenal. And it's true, right? We have to heal together. We are more alike than we are different. We want similar things and our disagreements are petty. We just have to put them aside. And these medicines truly bring us together anybody that's ever had the privilege of sharing a psychedelic journey with other people you you become family your family and it's true it's true it's true you know and there are there are places you know where where you can get this therapy right now it's very inaccessible for most people it's not something you can go to your doctor and get there There are ketamine-assisted clinics, therapy-assisted clinics.

Some of them are variable in their integrity of how they deliver the care, the medicine, with or without therapy. But those things are available. I think MDMA, this looks like it's slated for approval maybe early 2024 in the United States for treatment with therapy, not just MDMA, but with therapy. Celso may not be too far behind, but there are people who are going to Costa Rica or to Mexico or to Europe or other places where they're able to be doing these therapies legally or doing them underground in America. And I think we're seeing more and more people having these experiences.

I was at a conference with you and Paul, which was a traditional straight-up metal conference, and Paul asked, who here has not taken psychedelics or psilocybin, which is kind of a great way to ask people not to share something illegal, right? If you say, I've taken it, it means you've done something illegal. And literally half the audience about raised their hand,

which means the other half had done it. And this was not a Grateful Dead concert. This was a very conventional, you know, straight up business oriented healthcare conference. And I was like, wow, that's really remarkable. And I think things are really shifted. And I think we're in this really incredible moment in history where, you know, we have the potential to do healing at a level we haven't before. It's been known by ancient cultures that it's used in traditional ceremonial rituals, whether it's the South American Amazonian folks using ayahuasca or the Native Americans using peyote or in Mexico, the Wichita's using mescaline. There's just all sorts of cultures where this has just been embedded in there.

We were in Egypt together and we saw psychedelic mushrooms uh engraved in hieroglyphics on the wall of these 5 000 year old or older egyptian temples i'm like what so uh yeah we're just returning to it right like these lineages have been unbroken for many many many first nations on this planet and indigenous cultures on this planet like it's just us westerners that are just finally returning back to ourselves and you know i don't know about you but i don't know a doctor anymore and i don't know any nurses that have not had a psychedelic experience you probably hang out in different circles you know it's actually very it's very it's very, it's very surprising. It's very surprising. Some of the meetings you go to and people will say things that, you know, they're saying

because they've had a session. Well, I know it profoundly affected me for sure in my worldview when I was very young. So it's life changing. It is. Well, Pam, thank you so much for your work, for being an advocate, for moving the research along, for being in the trenches, working with real people, doing this work and seeing the profound changes. And I can't wait to see what comes next out of your work and research and how we all sort of make this not just sort of a marginal thing, but really standard of care for people with some of the most intractable problems that humanity suffers from. So thank you so much.

Yeah, well, it's a team effort. I just need to suffers from. So thank you so much. Yeah. Well, it's a team effort. I just need to say that. It's a team effort. Yes. Nothing we do at Roots to Thrive is based on any individual. It's a fully a team effort. And without everybody holding that blanket together,

we wouldn't have done nearly as much and we'll keep doing it. Well, thank you so much. Everybody wants to know more about the work that Pam is doing. You can go to roots to thrive.com. You can look at Michael Medica, which is some of the microdosing, um, research around how this works for various kinds of problems and the commercialization of it. Microdose me.com is the website for the research study, which I think anybody can join it by downloading the app. And, and I look forward to continue to kind of follow your work and track what you're doing. And I hope people listening to this have found something useful. If you have inspired, I've been inspired by, please share with your friends and family on social media. I think many

people can benefit from hearing what Pam has to say, leave a comment, how psychedelic use or treatment helped you. And we'd love to hear how it's changed your life and the things that you might've benefited from it. And we'll see you next time on The Doctor's Pharmacy. Hey everybody, it's Dr. Hyman. Thanks for tuning into The Doctor's Pharmacy. I hope you're loving this podcast. It's one of my favorite things to do and introducing you all the experts that I know and I love and that I've learned so much from. And I want to tell you about something else I'm doing,

which is called Mark's Picks. It's my weekly newsletter. And in it, I share my favorite stuff from foods to supplements, to gadgets, to tools to enhance your health. It's all the cool stuff that I use and that my team uses to optimize and enhance our health. And I'd love you to sign up for the weekly newsletter. I'll only send it to you once

a week on Fridays, nothing else, I promise. And all you do is go to drhyman.com forward slash pics to sign up. That's drhyman.com forward slash pics, P-I-C-K-S, and sign up for the newsletter and I'll share with you my favorite stuff that I use to enhance my health and get healthier and better and live younger longer. Hi, everyone. I hope you enjoyed this week's episode. Just a reminder that this podcast is for educational purposes only. This podcast is not a substitute for professional care by a doctor or other qualified medical professional. This podcast is provided on the understanding that it does not constitute medical or other professional advice or services. If you're looking for help in your journey, seek out a qualified medical practitioner.

If you're looking for a functional medicine practitioner, you can visit ifm.org and search their find a practitioner database. It's important that you have someone in your corner who's trained, who's a licensed healthcare practitioner, and can help you make changes, especially when it comes to your health.